Xencor

Biotechnology, Health Care, Therapeutics
Founded in 1/1/97
Monrovia, California, United States
http://www.xencor.com
For Profit

About Xencor

Xencor provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for the treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy. The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant-negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.

Company Metrics

  • Employees: 101-250
  • Monthly Visits: 12070
  • Tech Stack: 19 active products

Financial Information

  • Estimated Revenue: $10M to $50M
  • Total Funding: 133397653 USD
  • Last Funding: 25000000 USD (Post-IPO Equity)
  • Funding Status: IPO

Technology Stack

Xencor actively uses 19 products in their tech stack.

Market Presence

Industries: Biotechnology, Health Care, Therapeutics

Headquarters: Monrovia, California, United States

Leadership

  • Bassil Dahiyat - CEO LinkedIn
  • John Kuch - Senior Vice President and CFO LinkedIn
  • Allen Yang - Senior Vice President, Chief Medical Officer LinkedIn

Employees

  • John Desjarlais - Chief Scientific Officer (LinkedIn)